Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.63 |
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22118712 | 1.00 | CYP2D6 (0.63) | CYP2D6DHODHMAPTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL15264958 | 0.99 | CYP2D6 (0.62) | CYP2D6DHODHMAPTKCNH2LMNA | |
| SCHEMBL4153830 | 0.96 | CYP2D6 (0.58) | CYP2D6DHODHMAPTKCNH2LMNA | |
| Hydrochloric Acid SCHEMBL4138356 | 0.94 | CYP2D6 (0.57) | CYP2D6DHODHMAPTKCNH2LMNA | |
| SCHEMBL22529398 | 0.91 | CYP2D6 (0.55) | CYP2D6DHODHMAPTKCNH2LMNA | |
| SCHEMBL4160214 | 0.88 | CYP2D6 (0.50) | CYP2D6DHODHMAPTKCNH2LMNA | |
| SCHEMBL4027054 | 0.82 | SIRT1 (0.66) | CYP2D6LMNAALDH1A1SIRT1HSD17B10 | |
| SCHEMBL22856853 | 0.82 | DHODH (0.62) | CYP2D6DHODHMAPTKCNH2LMNA | |
| SCHEMBL4143065 | 0.82 | BRD3 (0.64) | CYP2D6DHODHMAPTKCNH2LMNA | |
| SCHEMBL20615427 | 0.82 | BRD3 (0.58) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490487-A | Polysubstituted tetrahydrocarbazole compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-02-21 | — | — | CN | disclosed |
| CN-118666733-A | Application of tetrahydrocarbazole micromolecule compounds in preparation of antiviral drugs and preparation method thereof | 中国人民解放军空军军医大学 | 2024-09-20 | — | — | CN | disclosed |
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| CN-107739371-B | Tetrahydrocarbazole micromolecule organic compound, application thereof in preparing antibacterial drugs and preparation method thereof | 华东师范大学 | 2020-08-25 | — | — | CN | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2006118607-A2 | HCV INHIBITORS WITH CARBAZOLE STRUCTURE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-20 | — | — | US | disclosed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| WO-2006065480-A2 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-1658068-A1 | NOVEL CYCLOALKYL'B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1654228-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1646610-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SmithKline Beecham Corporation (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005023245-A1 | NOVEL CYCLOALKYL’B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005005386-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004110999-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | CYP2D6 1458/4885DHODH 2499/4885MAPT 4489/4885 |
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC10A1, SLC47A1 | CYP2D6 1059/4885DHODH 1802/4885MAPT 4110/4885 |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | CYP2D6 660/4885DHODH 62/4885MAPT 1102/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | CYP2D6 1059/4885DHODH 1802/4885MAPT 4110/4885 |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | CYP2D6 660/4885DHODH 62/4885MAPT 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.